An increasing proportion of the population has acquired immunity through COVID-19 vaccination
and previous SARS-CoV-2 infection, ie, hybrid immunity, possibly affecting the risk of …

We used data of 32,542 prospective cohort study participants who previously received primary
and one or two monovalent booster COVID-19 vaccinations. Between 26 September and …

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination
against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 …

Objectives We estimated vaccine effectiveness (VE) of primary and booster vaccinations
against SARS-CoV-2 infection overall and in four risk groups defined by age and medical risk …

Background We aimed to estimate vaccine effectiveness against infection (VE-infection) and
against further transmission (VE-infectiousness) in a household setting during Delta and …

Objectives We describe health-related quality of life during the COVID-19 pandemic in the
general Dutch population and correlations with restrictive measures. Methods Data were …

VAccine Study COvid-19 (VASCO) is a cohort study with 5-year follow-up to assess the real-world
vaccine effectiveness (VE) of COVID-19 vaccines in the Netherlands. VASCO was …

INTRODUCTION: Adverse events (AE) such as pain at injection site or fever are common
after COVID-19 vaccination. We aimed to describe determinants of AE after COVID-19 …

Objectives To estimate the protective effect of previous infections and vaccinations on SARS-CoV-2
Omicron infection. Design Prospective cohort study Setting Community-based cohort…

Introduction We aimed to estimate vaccine effectiveness against infection (VE- infection)
and infectiousness (VE-infectiousness) in a household setting during Delta and Omicron. …